Myconoside-Rich Plant Extract Purification for UV and Radiation Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a myconoside-rich extract derived from in vitro systems of plants belonging to the genera Haberlea and Ramonda with controlled content for high biological value and effective chemo-, radio-, and UV protection, as existing methods do not provide sufficient concentrations or controlled protection.
Innovation Solution
A method to extract and purify myconoside and paucifloside from in vitro systems of Haberlea and Ramonda plants, involving aqueous or aqueous alcoholic extraction followed by solid-phase extraction with a hydrophobic interaction resin, yielding Extract 1 and Extract 2 with controlled phenylethanoid glycoside concentrations for use as chemo-, radio-, and UV protectors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If traditional agricultural techniques are used to cultivate medicinal plants, then cultivation is simple and low-cost, but the concentration of desired bioactive compounds is low and availability is limited
Solution Approach 1:
The patent extracts the valuable bioactive compounds (myconoside and paucifloside) from the plant matrix using systematic extraction procedures with solvents of varying polarity, obtaining concentrated extracts with controlled composition that achieve high bioactive compound concentrations without requiring extensive cultivation
Solution Approach 2:
The patent employs fractionation techniques that change physical and chemical parameters (solvent polarity, concentration, temperature) to separate and concentrate specific bioactive compounds from the plant material, transforming the crude extract into purified fractions with controlled composition and high active ingredient content
2Quantity of substance
If in vitro systems are used to produce bioactive compounds, then concentration and availability are significantly improved, but extraction and purification complexity increases
Solution Approach 1:
The patent divides the extraction and purification process into distinct sequential stages: initial extraction with aqueous or alcoholic solvents, filtration, concentration, and systematic fractionation using solvents of increasing polarity. Each stage isolates specific compound classes, making the complex process manageable and controllable while achieving high purity concentrations
Solution Approach 2:
The patent uses a systematic approach where physical and chemical parameters are changed progressively through each extraction stage (solvent polarity, temperature, concentration), allowing controlled separation of compounds based on their solubility characteristics and enabling precise control over the final extract composition
3Adaptability or versatility
If broad-spectrum extracts are used for protection, then multiple protective effects are achieved, but specificity and controlled protection levels are reduced
Solution Approach 1:
The patent creates extracts with different compositional profiles tailored for specific applications: Extract I is enriched in phenolic acids and flavonoids for general antioxidant protection, while Extract II is enriched in verbascoside and myconoside for enhanced UV and radiation protection. This allows selection of the appropriate extract based on the specific protective need, achieving both versatility and precision
Solution Approach 2:
The patent separates the broad-spectrum protective effects into distinct extract fractions with complementary profiles, allowing combination of extracts to achieve tailored protection levels for different applications (chemo-, radio-, UV protection), thereby maintaining versatility while enabling precise control over protection characteristics
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The purified extracts exhibit enhanced biological activities, providing significant antioxidant, antimutagenic, and anticlastogenic effects, making them suitable for use in human and veterinary medicine, nutritional supplements, and cosmetics as natural protectors against harmful effects.
Implementation Method 1
solid-phase extraction with a hydrophobic interaction resin
Data Source
AI summary
A myconoside containing extract is derived from in vitro systems of plants belonging to the family Gesneriaceae, in particular from the genera Haberlea and Ramonda, also including the species Haberlea rhodopensis Friv., Ramonda heldreichii (Boiss.) C. B. Clarke; Ramonda myconi (L.) Rchb.; Ramonda nathaliae Pancic & Petrovic, and Ramonda serbica Pancic, as well as from their hybrids. The extract is used in human and veterinary medicine, nutritional supplements and cosmetics as chemo-, radic- and UV protector. Extract 1 comprises 0.1 to 55.0 wt % PHE and free phenols, sugars, organic-, fatty- and amino acids, sterols up to 100 wt %, while Extract 2 comprises 55.0 to 99.9 wt % of PHE (in particular, myconoside and paucifloside), and phenolic compounds, mono-, disaccharides or their residues up to 100 wt %. Extracts 1 and 2 obtained according to this invention mainly consist of RHE (in particular, myconoside and paucifloside) within a broad spectrum and quantitative limits.